Tobira Therapeutics Inc. (TBRA) Downgraded by Cantor Fitzgerald to Hold
A number of other research firms also recently issued reports on TBRA. HC Wainwright reissued a buy rating on shares of Tobira Therapeutics in a research report on Tuesday, June 28th. Zacks Investment Research raised Tobira Therapeutics from a hold rating to a buy rating and set a $13.00 target price for the company in a research report on Wednesday, July 13th. Finally, Cowen and Company reissued a buy rating and issued a $11.00 target price on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Tobira Therapeutics currently has an average rating of Buy and an average price target of $16.75.
Shares of Tobira Therapeutics (NASDAQ:TBRA) opened at 39.09 on Wednesday. Tobira Therapeutics has a 1-year low of $3.76 and a 1-year high of $41.39. The firm has a 50-day moving average price of $6.61 and a 200 day moving average price of $8.48. The company’s market cap is $735.71 million.
Tobira Therapeutics (NASDAQ:TBRA) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.08. The business earned $1.06 million during the quarter. On average, equities analysts anticipate that Tobira Therapeutics will post ($2.65) earnings per share for the current year.
In other news, major shareholder A/S Novo sold 66,814 shares of Tobira Therapeutics stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $13.04, for a total value of $871,254.56. Following the completion of the transaction, the insider now directly owns 2,073,022 shares in the company, valued at $27,032,206.88. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.20% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. boosted its position in shares of Tobira Therapeutics by 27.9% in the second quarter. Franklin Resources Inc. now owns 750,000 shares of the biopharmaceutical company’s stock valued at $9,420,000 after buying an additional 163,600 shares during the period. BB Biotech AG acquired a new position in Tobira Therapeutics during the second quarter valued at approximately $5,878,000. Vanguard Group Inc. boosted its position in Tobira Therapeutics by 6.0% in the second quarter. Vanguard Group Inc. now owns 339,175 shares of the biopharmaceutical company’s stock valued at $4,260,000 after buying an additional 19,125 shares during the last quarter. AXA acquired a new position in Tobira Therapeutics during the second quarter valued at approximately $3,472,000. Finally, BlackRock Fund Advisors boosted its position in Tobira Therapeutics by 256.8% in the second quarter. BlackRock Fund Advisors now owns 227,775 shares of the biopharmaceutical company’s stock valued at $2,861,000 after buying an additional 163,943 shares during the last quarter. Institutional investors own 62.02% of the company’s stock.
Tobira Therapeutics Company Profile
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.